Introduction
============

Human immunodeficiency virus (HIV) infection leads to a progressive decline of immunity and eventually results in the initiation and progression of acquired immune deficiency syndrome (AIDS). The progressively weakened immune system of patients with AIDS increases the incidence of opportunistic infections and leads to higher mortality of patients with AIDS. CD4^+^ T cells are the targets of invading HIV-1; therefore, the counts of CD4^+^ T cells are used to evaluate the disease stage for patients with AIDS ([@b1-mmr-16-06-8854]). Additionally, gut-associated lymphoid tissue (GALT) is the biggest lymphoid tissue of the human body, which provides the specific anatomical and physiological environment required by CD4^+^ T cells and other immune cells ([@b2-mmr-16-06-8854]). GALT is also the primary target of HIV-1 infection; therefore, GALT was previously identified as the potential reservoir of HIV-1 due to the depletion of CD4^+^ T cells observed ([@b3-mmr-16-06-8854]--[@b5-mmr-16-06-8854]). This was followed by damage in intestinal mucosa and disorders of gut micro-ecology, which accelerated disease progression in patients with AIDS ([@b6-mmr-16-06-8854]--[@b9-mmr-16-06-8854]). The intestinal immune dysfunction following HIV infection may injure the gut barrier, leading to gut bacterial translocation into the blood ([@b10-mmr-16-06-8854],[@b11-mmr-16-06-8854]) and chronic immune activation ([@b11-mmr-16-06-8854]--[@b13-mmr-16-06-8854]). This may also increase the risks of other complications, such as cardiovascular disease, osteoporosis, neurodegeneration and metabolic disease ([@b13-mmr-16-06-8854]). In view of the fact that the exhaustion of CD4^+^ T cells from GALT was much earlier than that of peripheral blood for AIDS patients, CD4^+^ T cell counts in GALT may be used as potential biomarkers for predicting the mortality rates in patients with AIDS ([@b14-mmr-16-06-8854]). Highly active anti-retroviral therapy may improve CD4^+^ T cell counts of patients with AIDS; however, the restoration of the immune system is challenging, particularly the counts of CD4^+^ T cells in gut intestinal mucosa remain at low levels ([@b5-mmr-16-06-8854],[@b15-mmr-16-06-8854]). Concurrently, this chronic inflammation may provide additional activated CD4^+^ T cells as targets for HIV infection, subsequently accelerating AIDS progression and exacerbating the symptoms of the patient ([@b7-mmr-16-06-8854],[@b14-mmr-16-06-8854],[@b16-mmr-16-06-8854]). Therefore, the treatment of gut barrier damage in patients with AIDS would improve the reconstructing of the immune system and reduce the diffusion of HIV-1 in patients with AIDS.

MicroRNAs (miRNAs) are a type of endogenous non-coding single-stranded RNAs with a length of 21 to 23 nucleotides. miRNAs regulate the gene expression by employing the mechanism termed RNA interference at the post-transcription level, which may lead to the degradation of the target mRNA or suppression of its translation ([@b17-mmr-16-06-8854]). A previous study has predicted that miRNAs may regulate \>50% of human protein-coding genes ([@b18-mmr-16-06-8854]). miRNAs have important regulatory roles in different diseases by participating in various processes, such as cell proliferation and development ([@b19-mmr-16-06-8854],[@b20-mmr-16-06-8854]). Dysregulation of miRNAs was also detected in the disturbance of cellular processes of diabetes and cancer progression ([@b21-mmr-16-06-8854]). The function of miRNAs in the pathogenesis of AIDS has been previously illustrated in terms of the host cells aspect and the virus aspect ([@b22-mmr-16-06-8854]--[@b24-mmr-16-06-8854]). In the host miRNAs, miR-132 was identified to be upregulated following CD4^+^ T cell activation, which increased HIV-1 replication in CD4^+^ T cells ([@b22-mmr-16-06-8854]). Conversely, miR-198 inhibited HIV-1 gene expression and replication ([@b23-mmr-16-06-8854]). The HIV-1 tat protein also regulates miR-217 for the regulation of sirtuin 1, IκB kinase and phosphorylated nuclear factor-κB, subsequently inducing various effects on multiple pathways and cellular responses, such as p65-NFκB and AMPK signaling ([@b24-mmr-16-06-8854]). In addition to the aforementioned endogenous miRNAs of host cells, HIV-1 also encodes two miRNAs. One is miR-N367, which suppresses the HIV-1 nef protein and inhibits the transcription of HIV-1, thus maintaining the virus at a latent stage in patients with HIV infection where they are termed long-term non-progressors (LTNPs) ([@b25-mmr-16-06-8854]). The other miRNA is HIV1-miR-H1, which suppresses the expression of the apoptosis antagonizing transcription factor and the downstream B cell leukemia/lymphoma 2 and MYC proto-oncogene and downregulated the expression of cellular miR-149, which targets Viral Protein R of HIV-1, facilitating HIV-1 replication and impairing cellular responses to infection ([@b26-mmr-16-06-8854]). Therefore, previous studies have identified the complicated networks of miRNAs in HIV-1 and host cells that influenced the pathogenesis and progression of AIDS. However, the interactions between the miRNAs that have been identified, remain to be elucidated. Therefore, identifying the miRNAs active in the intestinal mucosa of patients with AIDS may elucidate the networks of miRNAs for HIV-infected patients and identify potential novel mechanisms of miRNA regulation in patients with HIV.

The present study isolated RNA from colon biopsy samples of HIV^+^ antiretroviral therapy-naïve (without therapeutic intervention) patients and HIV^−^ healthy individuals. The samples were subjected to miRNA array hybridization. MiRNAs with significantly different expression levels were identified between the HIV/AIDS and control groups with a threshold of P\<0.05. The target genes of the significantly different miRNAs were predicted and subsequent GO and KEGG pathway analyses were used to predict the potential signal pathways that may be associated with gut barrier dysfunction of patients with HIV infection and the potential disease progression. RT-qPCR was performed in order to verify the expression of the significantly expressed genes, which modulated the gut barrier dysfunction of patients with HIV infection.

Materials and methods
=====================

### Patients

Colon biopsy samples from a total of 26 male participants aged 27--53 years were collected by electron endoscopy from the First Affiliated Hospital of Kunming Medical University (Kunming, China) between January 2013 and January 2014 and informed consent was obtained. The HIV-infected antiretroviral therapy-naïve group contained 3 participants and other 3 healthy individuals were assigned to control group. Additional colon biopsies from 10 HIV-infected patients and 10 healthy control individuals were performed. The samples were immediately cryopreserved for transcriptional analysis. Peripheral blood samples were also collected at the time of the endoscopy. Detailed information on the clinical characteristics of the participants are presented in [Table I](#tI-mmr-16-06-8854){ref-type="table"}. HIV-infected individuals enrolled in the current study if they adhered to the following criteria: Antiretroviral therapy naïve; viral load of \>10,000 HIV-1 RNA copies/ml of plasma; and period for infection with HIV-1 \>1 year. The HIV-1 patients with current opportunistic or other infections were excluded from the present study. The procedures in the current study were approved by the Ethics Committee Review Board of Kunming Medical University.

### Total RNA extraction and quality inspection

Total RNA from each colon tissue sample was isolated with TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and purified with miRNeasy Mini kit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer\'s protocols. RNA quality and quantity were quantified using a NanoDrop spectrophotometer at a wavelength of 280 nm (ND-1000; Thermo Fisher Scientific, Inc., Wilmington, DE, USA). RNA integrity was determined by gel electrophoresis (1% agarose). Subsequently, the isolated RNA was purified using RNeasy Mini kit (Qiagen, Inc.) and the purity was examined with NanoDrop ND-1000.

### RNA labeling and array hybridization

Following quality control, the miRCURY Hy3/Hy5 Power labeling kit (Exiqon, Vedbæk, Denmark) was used for miRNA labeling according to the manufacturer\'s protocol. Subsequently, Hy3-labeled samples were hybridized on the miRCURY LNA Array (v.18.0; Exiqon) according to the array manual. The total mixture with hybridization buffer was hybridized to the microarray in a 12-Bay Hybridization system (hybridization system; NimbleGen Systems, Inc., Madison, WI, USA), which provided an active mixing action and a constant incubation temperature to improve hybridization uniformity and enhanced the signal. Following hybridization, the slides were washed three times using Wash buffer kit (Exiqon) and scanned using the Axon GenePix 4000B microarray scanner (Molecular Devices, LLC, Sunnyvale, CA, USA). GeneChip microarray experiments were conducted by KangChen Biotech (Shanghai, China).

### Microarray data analysis

Scanned images were imported into GenePix Pro version 6.0 software package (Molecular Devices, LLC) for grid alignment and data extraction. Replicated miRNAs were averaged and miRNAs with intensity ≥30 in all samples were selected for the calculation of the normalization factor. Expressed data were normalized using the median normalization. Significantly differentially-expressed miRNAs between the two groups were identified through fold-change and P\<0.05. A cut-off of \>2.0 fold-change of gene expression was used to identify miRNAs for analysis of hierarchical clustering patterns and downstream biofunctional assessment. The difference between two groups, evaluated by P-value was calculated based on a Student\'s t-test. Hierarchical clustering was performed to identify distinguishable miRNA expression profiling among samples. A \>2.0 fold-change and P\<0.05 cut-offs were selected to analyze gene expression data ([@b27-mmr-16-06-8854]), obtain sufficient information and generate a large data set to be used for downstream pathway analysis.

### Bioinformatics analysis

To predict the target genes of the differentially-expressed miRNAs, the 3 most popular databases, TargetScan ([@b28-mmr-16-06-8854]), miRanda ([@b29-mmr-16-06-8854]) and miRDB ([@b30-mmr-16-06-8854]) were fully referenced. In order to reduce false positive results, genes which were predicted by all 3 databases were selected as differential miRNA targets for further analysis. The miRNA expression changes were arranged from high to low according to the standardized intensity and fold-changes. The biological functions, including biological processes (BP, pathways and larger processes made up of the activities of multiple gene products), cellular compounds (CC, where gene products are active) and molecular function (MF, molecular activities of gene products) for the potential target genes, were analyzed using Gene Ontology (GO; [www.geneontology.org](www.geneontology.org)) terms. GO defines concepts/classes used to describe gene function and the relationships between these concepts. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was also performed with the target genes, which identified those most likely to be involved in intracellular signal transduction pathways. The major GO terms associated with BP and CC were manually summarized based on gene-term enrichment buttons provided for each functional group at P\<0.05.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

In order to confirm the expression profiles of key miRNAs, total miRNA was isolated from colon biopsies of 10 additional HIV^+^ patients and 10 normal individuals that were used as negative control. Poly-A tails were added to the miRNAs and reverse transcribed into cDNA with miRcute miRNA cDNA First-Strand Synthesis kit (Tiangen Biotech Co., Ltd., Beijing, China). For polyA tail addition, 1 µg RNA was mixed with 0.4 µl *E. coli* poly(A) polymerase (5 U/µl), 2 µl 10X poly(A) polymerase buffer and 4 µl 5X rATP solution for incubation at 37°C for 60 min. For reverse transcription, the above polyA reaction mix was further mixed with 0.5 µl Quant RTase and other additives for incubation at 37°C for 60 min. The quantity of miRNA was determined using a miRcute miRNA quantification kit (Tiangen Biotech Co., Ltd.). The forward primers for the miRNAs are as follows (U6 was used as miRNA reference): hsa-miR-199a-3 pF, 5′-CAGACAGTAGTCTGCACATTGGTTA-3′; hsa-miR-20b-5 pF, 5′-GCAAAGTGCTCATAGTGCAGGTAG-3′; hsa-miR-32-5 pF, 5′-CGCAGTATTGCACATTACTAAGTTG-3′; U6-F, 5′-CGATACAGAGAAGATTAGCATGGC-3′.

The primers for the mRNAs are as follows: (Actin was used as mRNA reference): ITGA5-F, 5′-ACCCAGACCCTGCTCATCCA-3′ and ITGA5-R, 5′-TGTGAATCGGCGAGAGTTTGTC-3′; FBN1-F, 5′-CGTGCACCCTATGCCAAGTT-3′ and FBN1-R, 5′-GCATTCCTCAGTACCCCAGG-3′. The thermocycling conditions are as follows: 95°C for 10 min; 45 cycles of 95°C for 15 sec and 60°C for 60 sec. The experiments were performed in triplicate with SYBR Green dye (Tiangen Biotech Co., Ltd.). Expression levels were calculated using the 2^−ΔΔCq^ method ([@b31-mmr-16-06-8854]) and data were presented as the mean ± standard error. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Differentially-expressed miRNA profiles in AIDS and healthy groups

In order to identify the miRNAs from the colon biopsy samples of AIDS patients and healthy controls, a 7th generation miRNA array containing 3,100 capture probes, covering all human, mouse and rat miRNAs annotated in miRBase 18.0, all viral miRNAs associated with these species and 25 miRPlus human miRNAs were used. The latter were proprietary miRNAs that were not found in miRBase. RNA quality was inspected prior to performing microarray hybridization. As presented in [Fig. 1A](#f1-mmr-16-06-8854){ref-type="fig"}, three bands were evident after RNA electrophoresis, denoting 28S, 18S and 5S RNA. Filtering was performed with microarray detection flags (presence or absence of signals), using thresholds of fold-change (≥2) and P\<0.05 to identify differentially-expressed miRNAs, 257 miRNAs were upregulated and 219 miRNAs were downregulated (data not shown) in the HIV-infected patients compared with the HIV-negative normal individuals. A heatmap was also generated to display a two-way hierarchical clustering of miRNAs and samples ([Fig. 1B](#f1-mmr-16-06-8854){ref-type="fig"}). The red color represents upregulated miRNAs, whereas green bars represent downregulated miRNAs. The three patients and the three control samples were grouped as different clusters, due to their similarities in miRNA expression profiles. A Volcano plot was also composed to visually identify the significantly differentially-expressed miRNAs between the two groups, based on the aforementioned thresholds ([Fig. 1C](#f1-mmr-16-06-8854){ref-type="fig"}). The red dots represent the miRNAs that had significantly altered expression level (P\<0.05), either upregulated (the red dots to the right) or downregulated (the red dots to the left).

### Prediction of target genes from differentially-expressed miRNAs

Functions of miRNAs were predicted by their target mRNAs; therefore, the putative target genes of differentially-expressed miRNAs between AIDS patients and healthy control individuals were predicted using the 3 aforementioned databases and the associated target genes were retrieved from all 3 databases. A total of 10 target genes of significantly downregulated miRNAs were predicted, including CSMD3, MLANA, RARG, EN1, BRSK1, ATXN7L2, RUSC2, ELN, EFNA5 and RNF39 ([Fig. 2A](#f2-mmr-16-06-8854){ref-type="fig"}). Additionally, 391 target genes of significantly upregulated miRNAs were also predicted ([Fig. 2B](#f2-mmr-16-06-8854){ref-type="fig"}).

### GO analysis for potential target genes of upregulated miRNAs

GO analysis of these target genes, which were predicted according to the differentially-expressed miRNAs, was performed, including BP, CC and MF. As only 10 overlapping target genes of downregulated miRNAs were predicted through the 3 databases, GO analysis for these 10 genes was not performed and the present study focused on GO and KEGG pathway analysis based on the target genes of the upregulated miRNAs.

The target genes were sorted into various BP according to their enrichment scores. The top 10 BP were identified as follows: Blood vessel development, vasculature development, heart development, cellular component morphogenesis, striated muscle tissue development, cell motion, cell morphogenesis, muscle tissue development, extracellular structure organization and regulation of cell morphogenesis ([Fig. 3A](#f3-mmr-16-06-8854){ref-type="fig"}).

The predicted target genes of upregulated miRNAs were also sorted into various categories of CC according to their enrichment scores, with the top 10 CC categories being listed as follows: Proteinaceous extracellular matrix, extracellular matrix, extracellular matrix part, membrane-bounded vesicle, vesicle, plasma membrane, extracellular region part, cytoplasmic membrane-bounded vesicle, cell projection and cytoplasmic vesicle ([Fig. 3B](#f3-mmr-16-06-8854){ref-type="fig"}).

The GO analysis was used to sort the predicted target genes of upregulated miRNAs were into various categories of MF ([Fig. 3C](#f3-mmr-16-06-8854){ref-type="fig"}). The top 10 categories of MF were: Heparin binding, glycosaminoglycan binding, transcription corepressor activity, pattern binding, polysaccharide binding, transcription repressor activity, transcription cofactor activity, transcription factor binding, SMAD binding and extracellular matrix structural constituent.

### KEGG pathway analysis of predicted target genes of upregulated miRNAs

KEGG pathway analysis was used to analyze the pathways, which were most likely to be altered by upregulated miRNAs ([Fig. 4](#f4-mmr-16-06-8854){ref-type="fig"}). The top 10 signaling pathways identified for the predicted target genes of upregulated miRNAs according to their enrichment scores were focal adhesion, ECM-receptor interaction, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, mechanistic target of rapamycin signaling pathway, gonadotropin releasing hormone signaling pathway, vascular endothelial growth factor signaling pathway, neutrophin signaling pathway and adherens junction.

### Confirmation of expression levels of key upregulated miRNAs

To confirm the expression levels of key miRNAs, RT-qPCR was performed with colon biopsies from 10 additional HIV-infected patients and 10 healthy control individuals. Normalized expression levels of AIDS patients, and the fold-changes from microarray data are presented in [Fig. 5A](#f5-mmr-16-06-8854){ref-type="fig"}. A total of 5 miRNAs were tested, 4 of which produced the consistent results with the microarray data. These miRNAs were hsa-miR-32-5p, hsa-miR-195-5p, hsa-miR-199a-3p and hsa-miR-20b-5p. The other miRNA, hsa-miR-590-5p, was upregulated in the samples of HIV-infected individuals from microarray data, but was demonstrated to be decreased in qPCR data. These miRNAs were selected as they were predicted to regulate some important genes that are implicated in intestinal mucosa dysfunction. For example, hsa-miR-32-5p was predicted to modulate the expression of integrin α5 (ITGA5), which has an important role in colon epithelium functions. All of them had high fold-changes of \>10 in the P group, and the expression of some miRNAs, including hsa-miR-32-5p, hsa-miR-195-5p and hsa-miR-20b-5p was confirmed by RT-qPCR, had fold-changes of 4.764, 8.914, 1.712 and 26.290, respectively. Additionally, expression of some putative target genes was also confirmed. As presented in [Fig. 5B](#f5-mmr-16-06-8854){ref-type="fig"}, expression of ITGA5 and fibrillin 1 (FBN1), the two putative target genes of upregulated hsa-miR-32-5p, were downregulated. Although the error bars are large for some groups due to the variability between the samples, the difference between the groups was significant (P\<0.05). These findings partially confirmed the accuracy of the microarray data and validated the further analysis performed.

Discussion
==========

The present study identified a large number of miRNAs with altered expression levels in HIV-infected individuals compared with healthy individuals. The data in the current study revealed that the regulation of some miRNAs was consistent with previous studies, such as miR-132, which was reported to be upregulated in activated CD4^+^ T cells and enhance HIV-1 replication ([@b22-mmr-16-06-8854]). Some miRNAs activate CD4^+^ T cells, thereby creating a favorable environment for HIV-1 replication ([@b32-mmr-16-06-8854],[@b33-mmr-16-06-8854]), such as miR-21, miR-142-3p/5p, miR-155, miR-181a and miR-27b ([@b34-mmr-16-06-8854]--[@b40-mmr-16-06-8854]). Among them, miR-181a was capable of activating CD4^+^ T cells by enhancing various associated pathways, including ERK and calcium flux ([@b40-mmr-16-06-8854]). The importance of miR-181a was also confirmed by the present study with a 3-fold increase in expression in patients with AIDS, in association with CD4^+^ T cell activation. Conversely, some inconsistencies were also detected between the current study and previous literature. For example, miR-142-3p/5p were downregulated in CD4^+^ T cells from patients with systemic lupus erythematosus, which may also lead to the over activation of CD4^+^ T cells via their targets, such as SAP, CD84, interleukin (IL)-10 ([@b37-mmr-16-06-8854]). However, the higher levels of miR-142-3p in the present study suggested a possible deactivation of CD4^+^ T cells. Additionally, lower levels of hiv1-miR-TAR-3p, an HIV-1-encoded miRNA, in HIV-infected individuals were observed, which may reveal that HIV-1 infection may trigger apoptosis. This was consistent previous studies of HIV-1 entry, facilitated by CD4 and CCR5 chemokine receptor. This elevated Fas levels in the cells and rendered the cells susceptible to apoptosis induced by the Fas/Fas ligand interaction ([@b41-mmr-16-06-8854]).

Using criterions of fold change ≥2 and P\<0.05 a total of 476 human and virus-derived miRNAs were identified as significantly altered in HIV/AIDS when compared with the control group (P\<0.05). Among them, a lower number of target genes of downregulated miRNAs were predicted compared with the target genes of upregulated miRNAs (10 vs. 391). These 10 genes include retinoic acid receptor γ (RARG), an antagonist of RAR signaling. Deficiency in retinoic acid receptors α (RARα) may lead to defects in CD4^+^ T cell activation ([@b42-mmr-16-06-8854]), which implied that the retinoic acid pathway through RARα was essential for CD4^+^ T cell effector responses. The reduced expression of some miRNAs, such as miR-622, may predict an increase in RARG. As a nuclear receptor, RARG shares functional similarities with other isoforms, such as RARα and RARβ ([@b43-mmr-16-06-8854]). Therefore, the transcription of associated genes would be altered. Therefore, it is possible that RARG may also contribute to the promotion of CD4^+^ T cell effector responses and acceleration of disease progression may occur, although definitive evidence is still required.

Although the expression patterns of some miRNAs were confirmed, their roles remain to be fully elucidated. As gene expression may be modulated by a broad range of biological factors, including other gene products, miRNAs, long non-coding RNA, prediction of changes in the expression of target genes only based on their regulator miRNAs may not be entirely reliable. By considering the aforementioned factors, GO and KEGG pathways analyses were performed, where the direction of the expression alterations (upregulation or downregulation) was not required. Therefore, the present study demonstrated pathways that are modulated by the differentially-expressed miRNAs. The GO and KEGG pathway analyses identified a number of pathways involved in heart development and cardiomyopathy development. Previous studies have determined that AIDS patients are more prone to be dilated cardiomyopathy and other heart diseases ([@b44-mmr-16-06-8854],[@b45-mmr-16-06-8854]). The actin, a, cardiac muscle 1 (ACTC1) gene, which encodes cardiac muscle α actin and is responsible for heart muscle contraction, was regulated by miR-30a-5p, miR-32-5p and miR-363-3p. Some of the validated miRNAs had important functions in AIDS and associated diseases. For example, nuclear factor of activated T-cells 3 (NFATC3) was a predicted target of hsa-miR-195-5p. Upregulation of hsa-miR-195-5p reduced the NFATC3 mRNA level, which confirmed by the mRNA microarray data (not shown). This protein is a member of the nuclear factors of activated T cells and regulates the expression of various cytokines, including IL-2 and tumor necrosis factor-a (TNF-α; [Fig. 5C](#f5-mmr-16-06-8854){ref-type="fig"}. Therefore, NFATC3 and its regulator hsa-miR-195-5p, are important for the immune response. Another important molecule is hsa-miR-32-5p, whose putative targets include RAB23, member RAS oncogene family, FBN1, Kruppel like factor 2 and ITGA5. These genes modulate multiple biological processes and components, such as the extracellular matrix. The expression for parts of these putative target genes were confirmed by RT-qPCR as presented in [Fig. 5B](#f5-mmr-16-06-8854){ref-type="fig"}.

Using the significantly changed miRNAs, the potential genes that may have crucial roles on regulating gut barrier dysfunction for HIV-infected patients were predicated using the DAVID comprehensive functional classification. Three pathways and an important immune response mediator, NFAT ([Fig. 5C](#f5-mmr-16-06-8854){ref-type="fig"}) were identified. A number of significantly upregulated miRNAs that may alter NFAT expression were identified, including miR-10a-5p ([@b46-mmr-16-06-8854]). NFAT, present in the cytosol, was translocated to the nucleus by T cell receptor stimulation and became a member of the nuclear factors for activating T cells transcription complex ([@b47-mmr-16-06-8854]). Due to the reduced NFAT expression, its translocation and regulatory functions may be severely impaired, leading to reduced levels of target cytokine expression, including IL-2, IL-4, IL-5, IL-10, interferon-γ, TNF-α. Their reduced expression may lead to autoimmune diseases and immune deficiency ([@b48-mmr-16-06-8854]).

It is of note that various altered miRNAs were identified to affect components of the extracellular matrix (ECM). These ECM molecules, including fibronectin, bind to integrin subtypes and affect multiple cellular processes, including cell-cell and cell-matrix interaction, cell motility and signaling pathways ([@b49-mmr-16-06-8854]). Actin polymerization was a prerequisite of highly concentrated CD4 and CXCR4 membrane receptors, which was determined to be essential for HIV propagation ([@b50-mmr-16-06-8854],[@b51-mmr-16-06-8854]). Therefore, actin polymerization and cytoskeleton remodeling was hijacked by infected cells to facilitate HIV attack and AIDS progression. Conditions may be worsened with weakened adherens junctions regulated by some upregulated miRNAs, such as miR-10b-5p ([@b52-mmr-16-06-8854]).

In conclusion, the present study provided a complete network of miRNAs with altered expression in HIV-infected individuals. Some of the alterations were consistent with those previously observed in literature ([@b22-mmr-16-06-8854],[@b40-mmr-16-06-8854]). Target genes of the significantly different miRNAs were predicted using the TargetScan, mirBase and miRanda databases, and the shared target genes from the three databases were selected. GO and KEGG pathway analyses focused on the 391 downregulated target genes and predicted important pathways including cell-EMC interaction and chemokine regulation. Alterations in these pathways are closely associated with CD4^+^T cell activation and reduction in chemokine levels. They also lead to gut barrier dysfunction of patients with HIV infection. miRNAs that potentially influence these target genes and pathways included hsa-miRNA-32-5p, hsa-miRNA-195-5p, hsa-miRNA-20b-5p and hsa-miRNA-590-5p. Expression of some miRNAs and target genes was confirmed with RT-qPCR. The present study identified the crucial roles of miRNAs in the regulation of the gut barrier dysfunction via multiple regulatory molecules and signaling pathways, which elucidated the underlying molecular mechanism for gut barrier dysfunction of HIV infection. The specific roles of these miRNAs in disease progression remain to be further investigated.
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![(A) RNA gel electrophoresis revealed clear 28S, 18S and 5S bands for all six samples, indicating good quality isolated RNA. (B) Heat map shows the results of two-way hierarchical clustering of miRNAs and samples. Each row represents a miRNA and each column represents a sample. The color scale shown at the top illustrates the relative expression level of a miRNA. red, high relative expression level; green, low relative expression level; N1, N2 and N3, HIV^−^samples; P1, P2 and P3, HIV^+^ samples. (C) Volcano plot shows the distribution of the detected miRNAs. The x-axis log~2~ (a fold-change) indicates the magnitude of fold change of P group vs. N group, and the y-axis log~10~ (P-value) indicates the significance. Red dots represent the miRNAs that have a significant increase of decrease in the P group.](MMR-16-06-8854-g00){#f1-mmr-16-06-8854}

![Predicted target genes of (A) downregulated and (B) upregulated miRNAs by overlapping three miRNA databases. miRNA, microRNA.](MMR-16-06-8854-g01){#f2-mmr-16-06-8854}

![GO analysis of predicted target genes of upregulated microRNAs. Top 10 (A) BP, (B) CC and (C) MF according to enrichment score. GO, gene ontology; BP, biological processes; CC, cellular compounds; MF, molecular functions.](MMR-16-06-8854-g02){#f3-mmr-16-06-8854}

![Kyoto Encyclopedia of Genes and Genomes pathway analysis based on the target genes of upregulated miRNAs. Top 10 signaling pathways according to enrichment score. ECM, extracellular matrix; mTOR, mechanistic target of rapamycin; GnRH, gonadotropin releasing hormone; VEGF, vascular endothelial growth factor.](MMR-16-06-8854-g03){#f4-mmr-16-06-8854}

![Confirmation of some miRNA and target gene expression and integrative pathway analysis. (A) Total miRNA was isolated from colon biopsies of 10 additional HIV^+^ patients and 10 normal healthy individuals. The quantity of miRNA was determined using the fold-changes from the microarray also being shown for comparison. \*P\<0.05. (B) miRNA expression levels of two important putative genes were confirmed by RT-qPCR. Triplicates were performed for each sample. Expression levels were calculated using the ΔΔC~q~ method, and data are presented as mean ± standard error \*P\<0.05. (C) An integrative schematic illustration was used to identify the miRNAs, target genes and pathways that are affected or were predicted to be affected in the patients. These pathways involve altered signaling pathways induced by ECM-cell interaction and many of them converge at the regulation of immune response-associated cytokines and chemokines. miRNA, microRNA; ITGA5, integrin subunit a 5; FBN1, fibrillin 1; N, HIV^−^ samples; P, HIV^+^ samples.](MMR-16-06-8854-g04){#f5-mmr-16-06-8854}

###### 

Patient data and clinical parameters of male Chinese HIV^+^ patients and normal individuals.

  ID     HIV status   CD4^+^ cell count, cells/µl)   Viral load, copies/ml   Age, years   Duration of infection, years
  ------ ------------ ------------------------------ ----------------------- ------------ ------------------------------
  N78    HIV-         836                            NA                      29           NA
  N121   HIV-         921                            NA                      47           NA
  N324   HIV-         865                            NA                      31           NA
  Y130   HIV+         217                            1790                    36           4
  G45    HIV+         414                            1326                    30           1
  W72    HIV+         205                            2204                    30           2
  N-1    HIV-         664                            NA                      27           NA
  N-2    HIV-         567                            NA                      27           NA
  N-3    HIV-         681                            NA                      29           NA
  N-4    HIV-         688                            NA                      32           NA
  N-5    HIV-         696                            NA                      28           NA
  N-6    HIV-         718                            NA                      34           NA
  N-7    HIV-         643                            NA                      33           NA
  N-8    HIV-         1089                           NA                      30           NA
  N-9    HIV-         810                            NA                      31           NA
  N-10   HIV-         769                            NA                      38           NA
  P-1    HIV+         106                            2088                    33           1
  P-2    HIV+         201                            1557                    41           5
  P-3    HIV+         206                            1432                    38           3
  P-4    HIV+         368                            2421                    33           3
  P-5    HIV+         140                            1805                    38           2
  P-6    HIV+         222                            1717                    37           2
  P-7    HIV+         231                            1314                    43           5
  P-8    HIV+         440                            1022                    51           4
  P-9    HIV+         117                            1840                    53           3
  P-10   HIV+         225                            1950                    45           3

NA, not applicable; HIV, human immunodeficiency virus.
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